40 results about "Low-density lipoprotein" patented technology

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

The invention belongs to the technical field of biological detection, and particularly relates to a detection method and a detection kit for oxidized low-density lipoprotein. The invention provides a novel application of quaternary ammonium salt chitosan in a kit, and particularly relates to application of quaternary ammonium salt chitosan with different molecular weights in an immunoturbidimetry detection process of oxidized low-density lipoprotein. When high-molecular-weight quaternized chitosan with the molecular weight of 100-200 kDa and low-molecular-weight quaternized chitosan with the molecular weight of 30-50 kDa are used as components of the oxidized low-density lipoprotein detection kit, the quaternized chitosan with different molecular weights can react with citrate radicals to form gel particles with different mechanical strengths; the content of the oxidized low-density lipoprotein can be detected through immunoturbidimetry, and the sensitivity and the linear range of the oxidized low-density lipoprotein detection kit are greatly improved and widened by using the quaternized chitosan with different molecular weights.

The invention belongs to the technical field of medical materials, and particularly relates to an adsorption material for removing low-density lipoprotein as well as a preparation method and application of the adsorption material. The adsorption material comprises a carrier and a ligand immobilized on the carrier, wherein the carrier is obtained by grafting and modifying polymer microspheres through glycidyl methacrylate, and the polymer microspheres comprise at least one of polystyrene divinyl benzene resin microspheres and polymethacrylate resin microspheres; the ligand contains a group with negative electricity.

The invention belongs to the technical field of medicines, and particularly relates to application of urolithin A and beta-nicotinamide mononucleotide in preparation of a medicine for treating diabetes. The invention finds that when the urolithin A and the beta-nicotinamide mononucleotide are independently used, the hypoglycemic effect on diabetic mice cannot be realized, and when the urolithin A and the beta-nicotinamide mononucleotide are jointly used, the symptoms of diabetes and insulin resistance caused by high fat diet can be remarkably improved; the glucose tolerance and the insulin tolerance are improved; meanwhile, the content of low-density lipoprotein and cholesterol in a mouse body is reduced, so that the risk of thrombus occurrence is reduced; in addition, combined medication can significantly reduce liver cell lipid accumulation and improve mitochondrial morphological abnormality. The invention provides a brand new technical scheme and experimental basis for treating diabetes caused by high fat diet and relieving insulin resistance, and has important medical application value.

This invention belongs to the field of traditional Chinese medicine technology. More specifically, it relates to the application of a processed product of Citrus reticulata peel or Citrus reticulata peel embryo (with bitterness removed) in the preparation of products for lowering lipids and preventing and treating hyperlipidemia. Compared with the original product, the processed product of Citrus reticulata peel or Citrus reticulata peel embryo provided by this invention significantly reduces bitterness while significantly enhancing its effects in lowering cholesterol and triglycerides and regulating blood lipids. This processed product helps maintain normal levels of serum cholesterol, triglycerides, and low-density lipoprotein, and can significantly improve liver damage caused by hyperlipidemia, thus having important application value in lowering lipids and protecting the liver.

The application belongs to the technical field of diagnostic markers, and particularly relates to a pathological diagnosis biomarker combination for adrenal Cushing syndrome and application. The pathological diagnosis biomarker combination comprises low density lipoprotein receptor (LDLR), 3-hydroxy-3-methylglutaryl coenzyme A synthetase 1 (HMGCS1) and cytochrome P450 11B1 (CYP11B1). The area under the ROC curve (AUC) of the pathological diagnosis biomarker combination can reach 0.881 (95% confidence interval (CI): 0.775-987; sensitivity: 85.7%; specificity: 85.0%), which indicates that the combination of LDLR, HMGCS1 and CYP11B1 as the pathological diagnosis biomarker combination for adrenal Cushing syndrome has high accuracy.

The invention belongs to the technical field of experimental animals, and particularly relates to application of reserpine in construction of animal models with normal high and low density lipoprotein and triglyceride values. The animal model construction method is minimally invasive, low in cost and good in reproducibility, has remarkable western medicine clinical biochemical index characteristics and a clear action mechanism, and can successfully and repeatedly establish an animal model with high and low density lipoprotein and normal triglyceride values. Conditions are created for clinical research on pathogenesis of related diseases, diagnosis and treatment of related diseases and screening, research and treatment of related disease mechanisms and drugs thereof, and good application prospects are achieved.

The present disclosure features antibodies and antibody fragments capable of binding to oxidized-low density lipoprotein, wherein the antibody is conjugated to a detectable label. The disclosure also provides methods for using the antibodies conjugated to a detectable label to detect the presence for atherosclerotic plaques in a subject as well as methods for diagnosing a subject with a cardiovascular disease.

The invention provides pediococcus acidilactici XZFMCC101.23156, a microbial preparation, an antibacterial composition and application of the pediococcus acidilactici XZFMCC101.23156, and belongs to the technical field of functional microorganisms. The preservation number of the pediococcus acidilactici XZFMCC101.23156 is GDMCC No: 66860, and the pediococcus acidilactici XZFMCC101.23156 can be used as a functional microbial agent to be applied in vivo to improve diseases such as hyperlipidemia and the like, and can also achieve the effect of reducing body weight. The result of the embodiment shows that the culture supernatant of the pediococcus acidilactici XZFMCC101.23156 can effectively reduce the total cholesterol, the triglyceride, the low-density lipoprotein and the high-density lipoprotein in a rat body. The pediococcus acidilactici XZFMCC101.23156 provides a new way for the development of oral probiotic preparations and the preparation of foods, drinks, health care products and medicines with the function of degrading cholesterol.

The invention provides a fermentation composition with a heart and cerebral vessel protection effect, a preparation method and application. The composition is prepared from raw materials consisting of radix ophiopogonis, radix puerariae and black sesame according to a specific ratio through sequential fermentation of plant lactobacillus KU01 and lactobacillus reuteri HX-LRE501. The preparation method is characterized in that KU01 is inoculated for first-stage hydrolysis fermentation, then pH is adjusted, and HX-LRE501 is inoculated for second-stage directional synthesis fermentation. According to the process, active ingredients such as conjugated linoleic acid and soluble polysaccharide are efficiently enriched through bacterial strain function synergy. The fermentation composition can effectively regulate blood fat, inhibit generation of oxidized low-density lipoprotein, relieve inflammation and regulate an intestinal flora structure through a multi-target synergistic effect, so that the anti-atherosclerosis effect is achieved. The composition is safe in raw materials, stable in process and suitable for large-scale production, and has a definite application prospect in preparation of foods or medicines for preventing and / or improving atherosclerosis and related cardiovascular and cerebrovascular diseases.

This invention belongs to the fields of biomedical materials and colloid chemistry, and discloses a structurally remodeled egg yolk low-density lipoprotein biomimetic liposome and its application in regulating cholesterol metabolism. The method includes extracting and purifying natural egg yolk low-density lipoprotein; selectively removing endogenous cholesterol by adding β-cyclodextrin under alkaline conditions; adding a phytosterol ethanol solution to the cholesterol-removed low-density lipoprotein dispersion, followed by incubation and dialysis purification to obtain the biomimetic liposome. The obtained biomimetic liposome uses partially cholesterol-removed egg yolk low-density lipoprotein as its structural framework, with phytosterols embedded in its phospholipid monolayer and lipid core interface. This biomimetic liposome can inhibit cholesterol micelle formation, reduce cholesterol absorption, promote macrophage cholesterol efflux, and inhibit macrophage foam formation. It can be used to prepare cholesterol metabolism regulating materials, functional delivery systems, and dietary supplement products.

The invention discloses characteristics and application of aerial microalgae Pilidiocystis sp. FDA-4 with high yield of C18, and belongs to the technical field of microalgae biology. The aerial microalgae FDA-4 is preserved in the China Center for Type Culture Collection on July 1, 2025, and the preservation number of the aerial microalgae FDA-4 is CCTCC NO: M 20251502. The strain has excellent low-pH adaptability and organic acid tolerance, can be directly cultured by using lactic acid bacteria waste liquid as the unique carbon source and nutrient medium, the optimal dilution ratio is 100 times, the biomass reaches 0.19 g / L after 12 days of culture, an exogenous nitrogen source does not need to be added and the initial pH does not need to be adjusted, the fatty acid composition is mainly C18 series, and the strain has a wide application prospect. The produced grease can be used for preparing products for reducing the low-density lipoprotein level and preventing cardiovascular diseases; meanwhile, the strain can efficiently convert nutrient substances in the lactic acid bacteria waste liquid, resource utilization of the waste liquid is achieved, and the strain has remarkable application value and industrialization potential.

The present application relates to a low-density lipoprotein low-speed centrifugal separation and purification method, comprising the following steps: using human serum, plasma and the remaining plasma after extracting other proteins as raw materials, adding PEG6000 to precipitate plasma low-density lipoprotein, then adding NaCl to adjust the liquid density and centrifugal, repeating the process, gradually changing the concentration and ratio of PEG6000 and NaCl until the plasma low-density lipoprotein precipitates and floats on the surface of the liquid after centrifugation, thereby separating from other proteins. The present application has the advantages of simple operation, large processing capacity, easy-to-get and cheap and safe reagents, low equipment requirements, high yield, and provides a convenient condition for various studies of plasma low-density lipoprotein.

The invention discloses an apolipoprotein B (ApoB) antibody related to oxidized low density lipoprotein (Ox-LDL) or a functional fragment of the apolipoprotein B antibody, and an application of the apolipoprotein B antibody and the functional fragment. The anti-Ox-ApoB antibody or the functional fragment thereof disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, and the antibody or the functional fragment thereof has relatively good specificity and sensitivity to Ox-ApoB, and can be used for detecting Ox-ApoB and / or Ox-LDL and used for auxiliary diagnosis of atherosclerosis by taking Ox-ApoB and / or Ox-LDL as a marker.

The invention discloses a fluorescent probe for detecting peroxynitrite ions as well as a preparation method and application thereof, and relates to the technical field of biomedical detection, and the structural formula of the fluorescent probe is shown in the specification. The prepared fluorescent probe for detecting the peroxynitrite ions has high selectivity and high sensitivity on the peroxynitrite ions, the response speed is high, fluorescence stability can be achieved within about 30 minutes, ratio type fluorescent quantitative detection of the peroxynitrite ions in an aqueous solution is achieved, the linear correlation is good, and the detection sensitivity is high. The rapid detection of the peroxynitrite ion level in an oxidation modified low-density lipoprotein induced atherosclerosis cell model is also realized, and good biocompatibility and application potential are realized.

Methods for identifying chronic hydrocephalus include assaying for an amount in a biological sample of one or more biomarkers selected from pyruvate dehydrogenase lipoamide kinase isozyme 4 (PDK4), phosphofructokinase-muscle (PFKM), low density lipoprotein receptor adaptor protein 1 (LDLRAP1), glucagon-like peptide-1 receptor (GLP-1R), hemoglobin subunit alpha 1 (HBA1), hemoglobin subunit alpha 2 (HBA2), heme oxygenase 1 (HMOX1), and combinations thereof. Methods for screening for a compound useful for treating chronic hydrocephalus are also provided and include contacting a cell with an effective amount of a test compound, and then detecting an expression or activity level of one or more of the biomarkers.

A herbal composition for the treatment of a variety of metabolic disorders in mammals, especially human beings, is disclosed. A method of preparing the herbal composition is also disclosed. The herbal composition treats and alleviates a plurality of metabolic disorders, including central obesity, high blood pressure levels, high blood sugar levels, stress-induced fatigue, and type 2 diabetes. The herbal composition comprises the extracts of Dolichos lablab, Achyranthes aspera, and at least one of Cinnamomum zeylanicum and Cinnamomum cassia. The aforementioned extracts are present in the herbal composition at a predetermined weight range. The aforementioned extracts are standardized to contain active compounds, including proanthocyanidins, saponins, polyphenols, and tannins, in a predetermined concentration and in predetermined purity levels. The herbal composition causes an enhancement of adiponectin levels and high-density lipoprotein (HDL) levels, and a reduction in the accumulation of adipose tissue, total cholesterol levels, triglyceride levels, and low-density lipoprotein (LDL) levels.

Provided herein, among other things, are novel and improved glycoproteins, including modified glycoproteins; engineered viral particles comprising such novel and modified glycoproteins; and methods for targeted delivery, for example, to immune cells such as T cells. In some aspects, the engineered viral particles allow targeted delivery of the cargo for various applications, including treating various conditions such as autoimmune diseases and cancer. In some aspects, the engineered viral particles comprise a viral fusogen that is a glycoprotein of Chandipura, Perinet, Piry, Jurona viruses, or variants thereof. In other aspects, the engineered viral particles comprise a modified vesiculovirus glycoprotein mutant, for example, with mutations at amino acids corresponding to positions I347 or R354 of Vesicular Stomatitis Virus G (VSV-G) that reduce binding to Low Density Lipoprotein Receptor (LDL-R).

The invention discloses application of INO80E in preparation of an anti-atherosclerosis medicine, and belongs to the technical field of biological medicines. The invention reveals for the first time that INO80E can interact with histone deacetylase 1 (HDAC1) so as to deacetylate a transcription factor YY1, so that vascular endothelial cell apoptosis is inhibited, and the purpose of delaying an atherosclerosis process is achieved. Experiments prove that the expression level of INO80E in an atherosclerosis model is remarkably reduced; overexpression of INO80E can effectively reverse endothelial cell apoptosis induced by oxidized low-density lipoprotein (ox-LDL) and restore expression balance of anti-apoptotic protein Bcl-2 and pro-apoptotic protein BAX. Therefore, the INO80E can be used as a brand new drug target for treating or preventing atherosclerosis related diseases, can be used for preparing diagnostic reagents or drugs, and has the advantages of no equipment dependence and strong targeting.

This invention belongs to the field of bioassay technology, and specifically relates to a method and kit for detecting oxidized low-density lipoprotein (ODL). This invention provides a novel application of quaternized chitosan in the kit, specifically using quaternized chitosan of different molecular weights in the immunoturbidimetric detection of ODL. Results show that when high molecular weight quaternized chitosan (100-200 kDa) and low molecular weight quaternized chitosan (30-50 kDa) are used as components of the ODL detection kit, the different molecular weights of quaternized chitosan react with citrate to form gel particles of varying mechanical strengths. This allows for the detection of ODL content via immunoturbidimetry. Furthermore, the use of quaternized chitosan of different molecular weights significantly improves the sensitivity and linear range of the ODL detection kit.

The application belongs to the field of biological medicine research and development, and particularly relates to application of umbilical cord mesenchymal stem cell-derived vascular endothelial precursor cells in preparation of medicines for preventing and treating atherosclerosis. By interfering with expression of related factors in a pyroptosis inflammatory signaling pathway of NLRP3, ASC, Caspase-1, GSDMD, IL-1β and IL-18 at a transcription and protein level, the serum triglyceride concentration, total cholesterol concentration and low-density lipoprotein concentration can be reduced, the serum oxidized low-density lipoprotein and oxygen free radical concentration can be reduced, the serum high-density lipoprotein concentration can be increased, and the atherosclerotic plaque area can be reduced and cell apoptosis in the atheromatous plaque can be inhibited.

The application discloses a gradient crosslinking preparation method of a high-selectivity blood low-density lipoprotein adsorption resin, and the adsorption resin is in a granular form, has a gradient crosslinking structure with gradually reduced crosslinking degrees from the outside to the inside in the radial direction, and forms a multistage pore structure of a large hole-mesopore-micropore inside; a lipoprotein recognition ligand is fixed on the resin particles, and an anti-protein contamination layer is arranged on the outer surface; during preparation, porous polymer microspheres are prepared through suspension polymerization, the diffusion process of a crosslinking agent from the outside to the inside is controlled to form the gradient crosslinking, then functional groups are introduced, the ligand is fixed, and surface modification is performed. Through the partition design of the outer anti-contamination layer, the middle layer recognition and the inner layer mass transfer, and the synergistic effect of the gradient crosslinking and the multistage pore structure, the selective adsorption capacity of the resin for low-density lipoprotein is significantly improved, non-specific protein adsorption is reduced, and the resin has good blood compatibility and regeneration stability.

The invention provides a self-anticoagulation blood fat adsorbent as well as a preparation method and application thereof, and the preparation method of the self-anticoagulation blood fat adsorbent comprises the following steps: preparing macroporous resin with suspension double bonds on the surface; the preparation method comprises the following steps: under the action of a first initiator, carrying out grafting reaction on macroporous resin with a carboxyl-containing monomer, a sulfonic acid group-containing monomer and a hydroxyl-containing monomer at the same time to prepare the self-anticoagulation blood fat adsorbent, wherein the carboxyl group-containing monomer, the sulfonic group-containing monomer and the hydroxyl group-containing monomer all contain unsaturated double bonds. The self-anticoagulation blood fat adsorbent provided by the invention has good strength, not only has good adsorption performance on low-density lipoprotein, but also has a self-anticoagulation effect, can be directly used for whole blood perfusion, and is beneficial to improving the safety of blood purification.

The invention belongs to the technical field of biomedical engineering and cell cryopreservation, and particularly relates to a cryoprotectant based on yolk low-density lipoprotein and application of the cryoprotectant. According to the invention, carrageenan is utilized to modify low-density lipoprotein to obtain a low-density lipoprotein-carrageenan compound, and then the low-density lipoprotein-carrageenan compound and L-proline serving as a permeable low-temperature protective agent are dissolved in water to obtain the cryoprotectant. According to the cryoprotectant, the toxicity of a traditional protectant can be reduced, and the elution step during resuscitation is simplified; ice crystal damage can be relieved, osmotic equilibrium and redox equilibrium can be adjusted, and the survival rate and the proliferation rate of cells can be increased.

This invention relates to a time-resolved fluorescence immunochromatographic assay kit for the determination of oxidized low-density lipoprotein (OxLDL) and its preparation method. The kit includes a detection card and a sample diluent. The detection card comprises, from bottom to top, a sample pad, a conjugate pad, a nitrocellulose membrane, absorbent paper, and a PVC base plate. The conjugate pad is coated with a mouse anti-OxLDL monoclonal antibody labeled with fluorescent microspheres. The nitrocellulose membrane has a detection line and a control line. The fluorescent microspheres have a core-shell structure, with a core of mesoporous silica loaded with rare-earth europium complexes and a shell of dense silica. The surface of the fluorescent microspheres is modified with amino groups. This invention constructs a silica-coated core-shell structure, encapsulating high-quantity-yield europium complexes within the core. The silica shell provides protection against external quenching factors while simultaneously providing abundant surface-active groups for antibody conjugation, achieving highly sensitive, stable, and reproducible quantitative detection of OxLDL.

The invention relates to the technical field of biological medicines, in particular to a medicine for synchronously improving polycystic ovarian syndrome hyperandrogenemia and lipid metabolism disorder, which takes a specific anti-ACBP neutralizing antibody as an active ingredient and plays a role by blocking two key pathological pathways mediated by ACBP: 1, blocking the interaction between ACBP and a transcription factor SREBP2 / HNF-4alpha, and 2, blocking a transcription factor SREBP2 / HNF-4alpha; the expression of a cholesterol synthesis rate-limiting enzyme HMGCR / HMGCS1 is down-regulated, and androgen synthesis substrates are reduced from the source; and secondly, the interaction between ACBP and mitochondrial transport protein TSPO / StAR is blocked, and the transport of cholesterol into mitochondria is inhibited, so that the generation of testosterone is reduced. The medicine can synchronously and remarkably reduce the serum testosterone level of a PCOS model animal, improve the polycystic form of an ovary and reduce the body weight, total cholesterol and low-density lipoprotein (LDL) level.

The present disclosure provides a technique for quantitatively detecting denatured LDL or stimulative AGEs in a quick and easy manner. The present disclosure also provides a device or kit for detecting or quantizing aberrant forms of biomarker molecules by forming a conjugate with the biomarker molecules, the device or kit including a membrane that carries out development of a specimen due to a capillary phenomenon, wherein: the membrane includes a detection part including a detection binding agent that specifically binds to the biomarker molecules or to competing molecules thereof, and a control part including a control binding agent that specifically binds to bound molecules and has a function for forming a conjugate with aberrant forms of the biomarker molecules or with competing molecules thereof; and the device or kit includes a specimen contact part and fluorescent nanoparticles as part of the membrane or as separate elements.

Provided herein, among other things, are novel and improved glycoproteins, including modified glycoproteins; engineered viral particles comprising such novel and modified glycoproteins; and methods for targeted delivery, for example, to immune cells such as T cells. In some aspects, the engineered viral particles allow targeted delivery of the cargo for various applications, including treating various conditions such as autoimmune diseases and cancer. In some aspects, the engineered viral particles comprise a viral fusogen that is a glycoprotein of Chandipura, Perinet, Piry, Jurona viruses, or variants thereof. In other aspects, the engineered viral particles comprise a modified vesiculovirus glycoprotein mutant, for example, with mutations at amino acids corresponding to positions I347 or R354 of Vesicular Stomatitis Virus G (VSV-G) that reduce binding to Low Density Lipoprotein Receptor (LDL-R).

The present application belongs to the technical field of pharmaceutical preparations, and particularly relates to application of cellular globin in preparation of a medicine for preventing and / or treating diabetes. The present application uses cellular globin for treating diabetes, especially type II diabetes. In the case of persistent hyperglycemia of diabetes, the content of cellular globin is increased to effectively eliminate the oxidative damage of various sugar metabolism byproducts to the body in various tissues and organs of the body, thereby slowing down the occurrence and development of complications caused by diabetes, which is specifically manifested in: reducing the content of blood sugar; reducing the content of total cholesterol; reducing the content of triglyceride; reducing the level of low-density lipoprotein; improving and restoring the normal morphological structure of pancreatic tissue; promoting the proliferation of islet beta cells; and promoting the secretion of insulin and glucagon of islets. In summary, the cellular globin can be used for treating diabetes.

The invention belongs to the technical field of medicines, and particularly relates to a composition for preventing and treating children obesity and a preparation method thereof. The composition comprises the following raw materials in parts by weight: 35-45 parts of active pharmaceutical ingredients and 8-15 parts of auxiliary materials, the active pharmaceutical ingredient is composed of sipunculus nudus polypeptide and catalpa glycoside in a mass ratio of 1: (1.5-3). The composition can inhibit the weight gain of mice with high fat diet, reduce the total cholesterol, triglyceride and low-density lipoprotein level in serum of the mice, and improve the high-density lipoprotein level in the serum. In addition, the composition can also improve liver fat accumulation and relieve fatty liver lesion caused by liver fat accumulation, and has no influence on renal functions.